The two barriers everyone shares
Step back and the whole track shares two chokepoints. First, delivery: nearly every molecular or genetic channel needs a gene put into the right cells — a viral vector, a promoter, an expression level — which is itself an unfinished gene-therapy problem with its own safety and durability questions. Second, readout or actuation reach: fields are weak and molecules are slow, so getting a usable signal in or out of a deep, intact human brain is unsolved for most of these methods.
The archive bound. However large a molecular recorder's stored capacity C_cell, its usable online rate is capped by the readout latency; when reading means fix-and-sequence, the effective real-time rate collapses toward zero. Molecular recording buys parallelism, not immediacy.
A resolution map
It helps to place the channels on two axes — specificity (how precisely you address cells) and speed (how fast you read or write). Molecular sensors are specific and fairly fast to read but shallow. Chemogenetics is specific but pharmacologically slow. Magnetothermal reaches deep but is coarse. Molecular recorders are maximally parallel but offline. No single method occupies the sweet corner — deep, fast, specific, bidirectional — which is exactly why none has displaced the electrode.
Why the future is biohybrid
The credible long-horizon vision is not a single winning modality but the biohybrid interface: living, engineered biology as the front end, coupled to a physical channel for reach. Think engineered sensor cells that transduce a neurotransmitter into a reporter a probe can read, or synthetic-biology circuits that store activity locally and release it on command. The nanoparticle-plus-channel of magnetothermal writing is already a small example of this logic — physics for reach, biology for specificity.
The gating factors are, in rough order, the maturity of gene delivery and clinical translation, the safety of chronically expressed foreign machinery, and our still-incomplete grasp of the neural code we would read or write. This is a decades-long research programme, and its honest promise is not to replace the electrode tomorrow but to reach places and cell types the electrode never will.